The EPS projection of The Medicines Company (NASDAQ:MDCO) for quarter ended 2016-09-30 is $-1.12. Last week, the EPS forecast was $-1.12 against target of $-1.12, a month earlier. Two months ago, this estimate was $-1.12 versus forecast of $-1.12 three months earlier, implying a deviation of 0%.
The Medicines Company (NASDAQ:MDCO) stated that 18 days ago, its stock price was positively revised 0 times while negative revisions were 1.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 1, 1, and 1, correspondingly.
EPS estimate downgrade for The Medicines Company (NASDAQ:MDCO) in the preceding 30, 120, 60 and 90 days were 0, 1, 1, and 1, correspondingly.
The Medicines Company (NASDAQ:MDCO) EPS target for the quarter closed 1 was $-1.12, based on 3 recommendations. As reported on 2016-05-09 the EPS was $-1.13. The change was $-0.28, implying a percentage deviation of -32.94%. The projections showed a standard deviation of 0.08.
Quarterly Sales Estimates
The Medicines Company (NASDAQ:MDCO) yearly sales prediction for the fiscal 2016 stands at $38.35 and the median estimate is at $38.35. Almost 2 analysts issued sales target.
Highest sales target is $39.5 while the lowest target is $37.2 showing standard deviation of 1.626%.
As many as 2 analysts have sales targets revised upside while 2 reduced sales estimates, implying a deviation of 0%.
Last month, 2 revised sales number projection on upside while 2 lowered the sales projections, implying a deviation of -10.606%.
A quarter ago, 2 hiked sales target and 2 reduced sales forecast. The Medicines Company (NASDAQ:MDCO) announced that the deviation in forecast was -26.179%.
1 Chart Pattern Every Investor Should Know